From Ethanol to Bio-Chemicals: Everything You Need to Know About Godavari Biorefineries IPO
Godavari Biorefineries Limited, a major player in the ethanol-based chemical industry, is all set to launch its Initial Public Offering (IPO) on October 23, 2024. The IPO size is Rs. 554.75 crore, with Rs. 325 crore as a fresh issue and Rs. 229.75 crore as an offer for sale (OFS). The public offering will close on October 25, 2024, and the company is expected to be listed on the stock exchanges by October 30, 2024. Here’s a closer look at what makes this IPO noteworthy and what potential investors need to know.
Key Details of the Godavari Biorefineries IPO
- IPO Size: ₹554.75 crore
- Fresh Issue: ₹325 crore (0.92 crore shares)
- Offer for Sale (OFS): ₹229.75 crore (0.65 crore shares)
- Price Band: ₹334 to ₹352 per share
- Lot Size: 42 shares (minimum 1 lot, maximum 14 lots)
- Listing Date: October 30, 2024
The primary objective of the IPO is to raise funds to repay Rs. 240 crore in outstanding loans, with the remaining amount allocated for general corporate purposes. Godavari Biorefineries Limited aims to strengthen its position as a leader in bio-based chemical production, especially ethanol.
Company Overview: A Pioneer in Ethanol-Based Chemicals
Established in 1956, Godavari Biorefineries Limited has become one of India’s leading manufacturers of ethanol-based chemicals. The company operates two state-of-the-art manufacturing facilities located in Bagalkot, Karnataka, and Ahmednagar, Maharashtra. With a production capacity of 570 KLPD for ethanol, the company caters to a wide range of industries, including food, beverages, pharmaceuticals, personal care, and cosmetics.
Notably, Godavari is the largest global producer of MPO (Mono Propylene Oxide) and the only Indian company to manufacture bio-ethyl acetate. Its client base extends across more than 20 countries, including the United States, China, Australia, and Germany.
Financial Overview: Recent Performance
While Godavari Biorefineries Limited is a well-established company, its recent financial performance presents some challenges. In FY24, the company saw a 16.28% decline in revenue, falling from ₹2,014.69 crore in FY23 to ₹1,686.67 crore. Additionally, its net profit dropped by 37.37%, from ₹19.64 crore in FY23 to ₹12.3 crore in FY24. By Q1 FY25, the company reported a net loss of ₹26.11 crore, further raising concerns about profitability.
However, there were some positive indicators, such as an increase in the EBITDA margin from 7.67% in FY23 to 8.77% in FY24. The company’s revenue mix is diverse, with major contributions from sugar (33.42%), bio-based chemicals (29.97%), and ethanol (33.30%).
Strengths and Weaknesses
Strengths:
- Diverse Product Portfolio: Godavari produces ethanol, bio-chemicals, and power, allowing it to cater to various industries and markets.
- International Reach: The company exports to over 20 countries, with international sales contributing 17% of revenue in FY23.
- Leadership and Expertise: Backed by the Somaiya Group’s 80+ years of experience, the company benefits from a visionary leadership team.
Weaknesses:
- Revenue Decline: The company’s declining revenue and profitability in recent financial periods are areas of concern.
- High Production Costs: The complex biorefinery process can lead to higher costs, affecting profitability.
- Dependence on Agriculture: The company’s reliance on agricultural inputs makes it vulnerable to climate-related disruptions.
Conclusion
Godavari Biorefineries Limited’s IPO is expected to generate interest, especially given the company’s leadership in ethanol-based production and bio-chemical manufacturing. However, recent financial challenges, such as declining revenue and profit margins, should be considered when evaluating this investment. The IPO comes at a time when the demand for ethanol and bio-based chemicals is rising, positioning Godavari to potentially benefit from favorable market trends despite its current financial hurdles.
Read More: Hyundai IPO Listing Price: Hyundai Motor India Share Price gets around 1.5% discount from IPO price
